What is ContraFect Corp. (CFRXQ) stock price today?

ContraFect Corp. (CFRXQ) is currently trading at $0.00.

What is CFRXQ P/E ratio?

ContraFect Corp.'s P/E ratio is 0.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CFRXQ return on equity (ROE)?

ContraFect Corp.'s return on equity (ROE) is 541.67%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is ContraFect Corp.'s market cap?

ContraFect Corp. has a market capitalization of $107.

OTC · Biotechnology

ContraFect Corp. (CFRXQ) Stock

$0.00 OTC: CFRXQ Healthcare

Valuation

Metric	Value
Price	$0.00
Market Cap	$107
P/E Ratio	0.00
P/B Ratio	0.00
P/S Ratio	0.00
EPS (TTM)	$-124.97
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	541.67%
ROA	-309.52%
ROCE	—
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.25
Current Ratio	0.86

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-32.0M	$-28.0M	$-34.0M	$-47.0M	$-57.0M
Net Profit	$-38.0M	$-13.0M	$-28.0M	$-20.0M	$-65.0M
EPS	$-396.35	$-123.57	$-98.95	$-44.12	$-124.97
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$33.0M	$35.0M	$51.0M	$67.0M	$21.0M
Total Liabilities	$27.0M	$19.0M	$38.0M	$17.0M	$33.0M
Cash	$8.0M	$24.0M	$15.0M	$17.0M	$9.0M
Borrowings	$0	$4.0M	$4.0M	$3.0M	$3.0M

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-26.0M	$-27.0M	$-33.0M	$-41.0M	$-46.0M
Investing Cash Flow	$17.0M	$22.0M	$-27.0M	$-12.0M	$32.0M
Financing Cash Flow	$-1.0M	$-2.0M	$-4.0M	$-4.0M	$-1.0M
Net Cash Flow	$1.0M	$16.0M	$-9.0M	$1.0M	$-8.0M
Free Cash Flow	$-26.0M	$-27.0M	$-33.0M	$-41.0M	$-46.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.09
FCF Yield	-43024299.07%
Quick Ratio	0.85
Interest Coverage	0.00
Return 1Y	-90.00%
Return 3Y	-100.00%
Return 5Y	—

Ownership

Insiders Held0.00%

Institutions Held11.10%

Institutions Float Held11.10%

Institutional Holder	Shares	Report Date
Ancora Advisors, LLC	28	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CDXS	$1.47	-2.00%	-5.06	$133.62M	0.00%
CELUCelularity Inc.	$0.75	+0.13%	-0.20	$21.74M	0.00%
DWTX	$1.81	+3.14%	1.42	$3.45M	0.00%
GPCRStructure Therapeutics Inc.	$53.36	-3.23%	-20.21	$3.07B	0.00%
INO	$1.04	+0.97%	-2.73	$55.73M	0.00%

About ContraFect Corp.

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

ContraFect Corp. (CFRXQ) stock trades at $0.00 with a market capitalization of $107. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, ContraFect Corp. generates a return on equity (ROE) of 541.67% — well above the market average, a sign of a high-quality business, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.contrafect.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides